AP2014007645A0 - Sustained-release preparation - Google Patents

Sustained-release preparation

Info

Publication number
AP2014007645A0
AP2014007645A0 AP2014007645A AP2014007645A AP2014007645A0 AP 2014007645 A0 AP2014007645 A0 AP 2014007645A0 AP 2014007645 A AP2014007645 A AP 2014007645A AP 2014007645 A AP2014007645 A AP 2014007645A AP 2014007645 A0 AP2014007645 A0 AP 2014007645A0
Authority
AP
ARIPO
Prior art keywords
sustained
release preparation
release
preparation
Prior art date
Application number
AP2014007645A
Other languages
English (en)
Inventor
Yumiko Ishii
Kaoru Takenaka
Yutaka Tanoue
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007645(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AP2014007645A0 publication Critical patent/AP2014007645A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
AP2014007645A 2011-10-21 2012-10-19 Sustained-release preparation AP2014007645A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
AP2014007645A0 true AP2014007645A0 (en) 2014-05-31

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007645A AP2014007645A0 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Country Status (29)

Country Link
US (1) US9907789B2 (xx)
EP (1) EP2768487B1 (xx)
JP (1) JP6093762B2 (xx)
KR (1) KR20140081826A (xx)
CN (1) CN104039313A (xx)
AP (1) AP2014007645A0 (xx)
AR (1) AR088398A1 (xx)
AU (1) AU2012326976B2 (xx)
BR (1) BR112014008744A2 (xx)
CA (1) CA2852417A1 (xx)
CL (1) CL2014000992A1 (xx)
CO (1) CO6960544A2 (xx)
CR (1) CR20140213A (xx)
DO (1) DOP2014000077A (xx)
EA (1) EA201490840A1 (xx)
EC (1) ECSP14013328A (xx)
IL (1) IL232114A0 (xx)
IN (1) IN2014DN03169A (xx)
MA (1) MA35717B1 (xx)
MX (1) MX2014004679A (xx)
NZ (1) NZ624275A (xx)
PE (1) PE20141189A1 (xx)
SG (2) SG2014012025A (xx)
TN (1) TN2014000152A1 (xx)
TW (1) TW201323018A (xx)
UA (1) UA113858C2 (xx)
UY (1) UY34403A (xx)
WO (1) WO2013058409A1 (xx)
ZA (1) ZA201403103B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34403A (es) 2011-10-21 2013-05-31 Takeda Pharmaceutical Preparación de liberación sostenida
MD20140063A2 (ro) 2012-04-20 2014-12-31 Gilead Sciences, Inc. Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
PL175026B1 (pl) 1992-09-18 1998-10-30 Yamanouchi Pharma Co Ltd Preparat typu hydrożelu o przedłużonym działaniu
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR101363679B1 (ko) 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (xx) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
WO2004082665A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
TW200510002A (en) 2003-06-06 2005-03-16 Takeda Chemical Industries Ltd Solid pharmaceutical preparation
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
JP4739189B2 (ja) 2004-04-14 2011-08-03 武田薬品工業株式会社 固形製剤
CA2578474A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
US20080226719A1 (en) 2005-09-22 2008-09-18 Roses Allen D Combination of Rosiglitazone and Donepezil for Improvement of Cognitive Function
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
PE20110019A1 (es) 2005-12-22 2011-01-27 Takeda Pharmaceutical Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
TWI449542B (zh) 2006-03-30 2014-08-21 Nippon Zoki Pharmaceutical Co 固形醫藥製劑
CL2007001195A1 (es) 2006-04-27 2008-01-04 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un nucleo con un compuesto derivado de bencimidazol y una grasa o aceite, una primera capa que comprende un polimero de alto peso molecular que recubre el nucleo y una segunda capa que comprende pioglitazona, util para tratar enfermedades circulatorias.
US9095519B2 (en) 2007-02-09 2015-08-04 Alphapharm Pty Ltd Dosage form containing two or more active pharmaceutical ingredients in different physical forms
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010039690A1 (en) 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) * 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
KR20180050420A (ko) * 2011-01-10 2018-05-14 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
UY34403A (es) 2011-10-21 2013-05-31 Takeda Pharmaceutical Preparación de liberación sostenida
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
KR20140081826A (ko) 2014-07-01
UY34403A (es) 2013-05-31
CR20140213A (es) 2014-06-18
AU2012326976B2 (en) 2017-08-17
WO2013058409A1 (en) 2013-04-25
CO6960544A2 (es) 2014-05-30
TN2014000152A1 (en) 2015-09-30
SG10201700121YA (en) 2017-03-30
AR088398A1 (es) 2014-05-28
IN2014DN03169A (xx) 2015-05-22
MA35717B1 (fr) 2014-12-01
CN104039313A (zh) 2014-09-10
DOP2014000077A (es) 2014-07-15
IL232114A0 (en) 2014-06-30
JP6093762B2 (ja) 2017-03-08
ECSP14013328A (es) 2014-05-31
US9907789B2 (en) 2018-03-06
NZ624275A (en) 2016-09-30
EP2768487A1 (en) 2014-08-27
AU2012326976A2 (en) 2014-06-12
CL2014000992A1 (es) 2014-09-05
TW201323018A (zh) 2013-06-16
EP2768487B1 (en) 2020-06-03
ZA201403103B (en) 2015-08-26
US20140248362A1 (en) 2014-09-04
EA201490840A1 (ru) 2014-08-29
BR112014008744A2 (pt) 2017-04-18
JP2014530802A (ja) 2014-11-20
AU2012326976A1 (en) 2014-05-29
PE20141189A1 (es) 2014-09-24
UA113858C2 (xx) 2017-03-27
MX2014004679A (es) 2014-08-01
SG2014012025A (en) 2014-06-27
CA2852417A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
DK3505720T3 (en) Cementering under styret tryk
DK3798230T3 (en) Terapeutiske antistoffer
EP2755962A4 (en) AZAINDAZOLES
EP2715659A4 (en) ABOUT FEED
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2723631A4 (en) QUADFOILER
HK1200314A1 (en) R()-n-methyl-propargyl-aminoindan r()-n---
SG10201604667YA (en) Pharmaceutical preparation
HK1200315A1 (en) R()-n-formyl-propargyl-aminoindan r()-n---
EP2762167A4 (en) EASY SOLID PREPARATION TO TAKE
EP2695208A4 (en) MICRO-THERMOCOUPLE
EP2679138A4 (en) Borescope
GB201105298D0 (en) Pharmaceutical preparation
GB201301300D0 (en) No details
EP2708561A4 (en) BIO-PIN
GB201119167D0 (en) Novel bachteriophages
DK2770906T3 (en) Applanationstonometer
EP2684382A4 (en) EARPHONES
ZA201403103B (en) Sustained-release preparation
PL2691119T3 (pl) Preparat farmaceutyczny
EP2698098A4 (en) campimeter
EP2694655A4 (en) pavec
HK1198841A1 (en) Plate-film forming member
IL228357A0 (en) solid preparation
EP2702929A4 (en) campimeter